$OMER In the third quarter Jazz Pharmaceuticals Conference Call, Dr. Robert Iannone, Executive Vice President of Research and Development, announced that the company has discontinued its research on stem cell transplant-associated thrombotic microangiopathy for its drug candidate defibrotide. Defibrotide (aka Defitelio) is a mixture of oligonucleotides used to treat veno-occlusive disease of the liver in bone marrow transplant patients.
  • 10
  • 1